Go to
JCI Insight
About
Editors
Consulting Editors
For authors
Alerts
Advertising/recruitment
Subscribe
Contact
Current Issue
Past Issues
By specialty
Cardiology
Gastroenterology
Immunology
Metabolism
Nephrology
Neuroscience
Oncology
Pulmonology
Vascular biology
All...
Videos
Conversations with Giants in Medicine
Author's Takes
Reviews
Reviews
View all reviews...
Review Series
Mechanisms Underlying the Metabolic Syndrome (Oct 2019)
Reparative Immunology (Jul 2019)
Allergy (Apr 2019)
Biology of familial cancer predisposition syndromes (Feb 2019)
Mitochondrial dysfunction in disease (Aug 2018)
Lipid mediators of disease (Jul 2018)
Cellular senescence in human disease (Apr 2018)
View all review series...
Collections
Recently published
In-Press Preview
Commentaries
Concise Communication
Editorials
Viewpoint
Scientific Show Stoppers
Top read articles
Clinical Medicine
JCI This Month
Current issue
Past issues
V3-specific neutralizing antibodies in sera from HIV-1 gp160-immunized volunteers block virus fusion and act synergistically with human monoclonal antibody to the conformation-dependent CD4 binding site of gp120. NIH-NIAID AIDS Vaccine Clinical Trials Network.
D C Montefiori, … , L A Cavacini, M R Posner
D C Montefiori, … , L A Cavacini, M R Posner
Published August 1, 1993
Citation Information:
J Clin Invest.
1993;
92(2)
:840-847.
https://doi.org/10.1172/JCI116658
.
View:
Text
|
PDF
Category:
Research Article
V3-specific neutralizing antibodies in sera from HIV-1 gp160-immunized volunteers block virus fusion and act synergistically with human monoclonal antibody to the conformation-dependent CD4 binding site of gp120. NIH-NIAID AIDS Vaccine Clinical Trials Network.
Text
PDF
Abstract
Authors
D C Montefiori, B S Graham, J Zhou, J Zhou, R A Bucco, D H Schwartz, L A Cavacini, M R Posner
×
Full Text PDF |
Download
(1.79 MB)